Therapeutic plasma exchange in CNS inflammatory demyelinating disorders: time is brain and spine?

Jun 04 2020 , India

Start a topic


TPE has a role in the management of various immune-mediated neurological disorders including CNS inflammatory demyelinating disorders (CNS-IDD), often as second line treatment following high dose steroids in part due to perceived risk, which inevitably result in delays in accessing TPE. There has been limited evidence such delays impact long-term outcome, however emerging data suggests that even 10-14 days, typical of when TPE is reserved for steroid-unresponsive patients, may adversely affect outcomes. We review TPE use in CNS-IDD, focusing on emerging data on timing and implications for clinical practice.

Read More..

Share Your Views

By registering, using and interacting on this website, you represent and warrant that you are a registered medical practitioner under the governing law of the country you reside or represent and are lawful citizens